Memo Therapeutics announced closing a CHF 14 million Series B financing from Swisscanto Invest by Zürcher Kantonalbank et al

Biotech Health services Manufacturing

Investments

06 November 2020

Memo Therapeutics (company)

Biotech Health services Manufacturing

Total investments received (USD): 112.24m

Round value (USD): 15.33m

Round investors: Bernina BioInvest Jaquet Partners Verve Ventures Redalpine Schroder Adveq Swisscanto Invest

Industry: Biotech Health services Manufacturing

Hardware Health services Manufacturing Software Services

Investments 06 April 2021

Health services Manufacturing

Investments 22 September 2020

Hardware Health services Manufacturing

Investments 19 August 2020